1231P - Efficacy of first-generation EGFR-TKIs on patients with NSCLC harboring EGFR uncommon mutations: a pooled analysis

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Anticancer Agents
Non-Small Cell Lung Cancer
Biological Therapy
Presenter Yiyin Zhang
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors Y. Zhang1, S. Tang2, J. Zhang1, Q. He1, J. He1, W. Liang1
  • 1Department Of Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, 510120 - Guangzhou/CN
  • 2Department Of Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN



NSCLC Patients with common sensitive EGFR mutations (deletion in exon 19 or L858R mutation in exon 21) benefit remarkably from first-generation EGFR-TKIs (gefitinib and erlotinib). In this meta-analysis, we aim to investigate their treatment efficacy in patients with uncommon EGFR mutations (S768I, L861Q, G719X, R705K, etc.) by comparing with that in patients with common mutations.


We searched PubMed for eligible studies from the date of inception to 31th December, 2015. Overall objective response rate (ORR) and 6-month progression free survival (PFS) rates were estimated by fix-effect model and relative effects were presented using odds ratio (OR). Mutations within the same exons were grouped in the subgroup analyses.


Of 6404 patients from 13 included studies, 466 (7.3%) patients were diagnosed as EGFR uncommon mutations and chose gefitinib and erlotinib as any line of treatment. In single-arm synthesis, the overall ORR in uncommon and common mutations was 34.0% (95% CI 22.5 to 45.5) and 71% (66.7 to 75.3), respectively. Direct comparison indicated significantly less response in uncommon-mutation patients (OR = 0.30, 95% CI 0.23 to 0.41, P 


Compared with those in sensitive mutations, first-generation EGFR-TKIs presented less clinical benefits in uncommon mutations; but the responses are still considerable, historically compared with that of chemotherapy, especially in complex mutations. First-generation EGFR-TKIs remained an option for uncommon mutations but decision-making should be cautious. Exact efficacy in each specific mutation site merits future studies with larger sample size.

Clinical trial identification

Legal entity responsible for the study



The first affiliated hospital of Guangzhou medical university


All authors have declared no conflicts of interest.